Article info
PDFColorectal
Research
Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?
- Correspondence to Dr Ramesh Arasaradnam, Department of Gastroenterology, University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, UK; R.Arasaradnam{at}warwick.ac.uk
Citation
Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?
Publication history
- Received November 20, 2013
- Revised February 8, 2014
- Accepted February 26, 2014
- First published March 17, 2014.
Online issue publication
April 19, 2016
Article Versions
- Previous version (19 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/